AP
BPMC

AtonRa Partners’s Blueprint Medicines BPMC Stock Holding History

AtonRa Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,505
Closed -$863K – 127
2022
Q1 		$863K Buy
13,505
+394
+3% +$28.3K 0.47% 81
2021
Q4 		$1.4M Buy
13,111
+873
+7% +$91.3K 0.49% 73
2021
Q3 		$1.26M Buy
12,238
+841
+7% +$78.3K 0.42% 86
2021
Q2 		$1M Buy
11,397
+2,674
+31% +$245K 0.37% 94
2021
Q1 		$848K Buy
8,723
+1,991
+30% +$199K 0.38% 98
2020
Q4 		$755K Buy
+6,732
New +$709K 0.37% 82

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AtonRa Partners's BPMC Position: Q2 2022 in Review

AtonRa Partners sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 13,505 shares — an estimated $863K sold.

AtonRa Partners first reported a position in BPMC in Q4 2020 and held it in 6 quarters. The position peaked at $1.4M in Q4 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • AtonRa Partners reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • AtonRa Partners sold 13,505 Blueprint Medicines shares in Q2 2022, an estimated $863K.
  • AtonRa Partners first reported a position in Blueprint Medicines in Q4 2020 and held it in 6 quarters.
  • AtonRa Partners's Blueprint Medicines position peaked at $1.4M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on AtonRa Partners's 13F filing for Q2 2022, filed 15 Aug 2022.